INS and cancer: On the other hand, T2DM patients who were treated with metformin, an insulin sensitizer, showed a reduced risk of cancer (odds-ratio for any exposure to metformin was 0.79) (Hemkens et al., 2009; Grouven et al., 2010; Rensing et al., 2010).